Regulatory UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy BioPharma DiveNews of the submission, which would be the first for UniQure s closely watched treatment, comes as the therapy faces an uncertain future in the U.S.NeuroscienceRead full story pharminent April 30, 2026 (Last updated: May 1, 2026) BioPharma Dive News of the submission, which would be the first for UniQure s closely watched treatment, comes as the therapy faces an uncertain future in the U.S. Neuroscience Read full story Post navigation Previous: Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launchNext: Parexel buys Vitrana to boost patient safety toolkit Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026